June 1999

Date: June 21, 1999Scientists Ranked by Number of Hot Papers and The Red Hot Research Papers of 1998 Editor's Note: Readers often tell us that their favorite element of The Scientist is the Hot Papers page. Here, scientists themselves get a chance to delve into what made the research paper to which they contributed significant enough to be cited in a large number of other papers over the past two years. In this issue, we have expanded the traditional Hot Papers page to four pages. We also have

Edited by: Nadia S. Halim B. Pitt, R. Segal, F.A. Martinez, G. Meurers, A.J. Cowley, I. Thomas, P.C. Deedwania, D.E. Ney, D.B. Snavely, P.I. Chang, "Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)," The Lancet, 349:747-52, 1997. (Cited in more than 230 papers since publication) Comments by Bertram Pitt, professor of medicine, division of cardiology, University of Michigan, Ann Arbor, and Robert Segal, dir

Edited by: Eugene Russo H. Ni, J. Engelbrecht, S. Brunak, G. von Heijne, "Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites," Protein Engineering, 10:1-6, 1997. (Cited in more than 250 papers since publication) Comments by Henrik Ni, Center for Biological Sequence Analysis, Department of Biotechnology, The Technical University of Denmark, Lyngby, Denmark J. Kling, "Opportunities abound in pharmacogenomics," The Scientist, 13[10]:16, May 10, 19

Edited by: Paul Smaglik G.G.J.M. Kuiper, B. Carlsson, K. Grandien, E. Enmark, J. Haggblad, S. Nilsson, J.A. Gustafsson, "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and ß ," Endocrinology, 138:863-70, March 1997. (Cited in more than 265 papers since publication) Comments by Jan-Åke Gustafsson, professor and chairman, Department of Medical Nutrition, Karolinska Institute, Huddinge, Sweden, and chairman, Department of Bi

Edited by: Paul Smaglik S.C. Chandrasekharappa, S.C. Guru, P. Manickam, S. Olufemi, F.S. Collins, M.R. Emmert-Buck, L.V. Deblenko, Z. Zhuang, I.A. Lubensky, L.A. Liotta, J.S. Crabtree, Y. Wang, B.A. Roe, J. Weisemann, M. Boguski, S.K. Agarwal, M.B. Kester, Y.S. Kim, C. Heppner, Q. Dong, A.M. Spiegel, A.L. Burns, S.J. Marx, "Positional cloning of the gene for Multiple Endocrine Neoplasia-Type I," Science, 276:404-7, 1997. (Cited in more than 200 papers since publication) Francis S. Collins C

WHY X Y? Cloning is not just for females anymore. The same University of Hawaii researchers that cloned 50 healthy female mice a year ago (T. Wakayama et al., "Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei," Nature, 394:369-74, July 23, 1998) recently reported the first-ever cloning of an adult male mouse (T.W. Wakayama, R. Yanagimachi, "Cloning of male mice from adult tail-tip cells," Nature Genetics, 22:127-8, June 1999). Named "Fibro" after the fibro

I was delighted to read Paul Smaglik's recent article regarding the role of supplements in disease prevention.1 He presented the breadth of expertise that can be found among "nutritionists." The role of supplements should not be controversial, and whole foods and supplements can be used together to compose a healthy diet. Unfortunately, though, the nutrition scientific community has not been progressive, and even the National Academy of Sciences has recommended that Americans obtain their nutr

Publication constraints are not new for those who serve in certain institutions and commercial organizations, including the corporate industries.1 Whatever is said and done, federal funding or government funds are critical for the development of basic research. Basic research is the foundation on which applied research is built. If university funding dwindles, industries will dominate research. Once an industry promotes research, it becomes obligatory for the scientist to follow its regulations

I really enjoyed the article by Ramie Leibnitz entitled "The NIH Postdoc Experience."1 It was an entertaining and enlightening piece with a serious overtone: that women, despite similar age and number of years post-Ph.D., earn approximately $1,000 less per year than men as postdocs at the National Institutes of Health (NIH). Although Dr. Leibnitz itemized what did NOT account for this (e.g., numbers of publications), she did not offer any explanations for this disturbing difference. If true, th

The Atlantic halibut has all but disappeared from New England waters, but once it was plentiful there. Like the now-depleted Atlantic cod and many runs of salmon in the Pacific Northwest, halibut have been nearly wiped out where they previously were thought to be countless. When fish disappear, the effects can be devastating to a fishing community's economy, to its sense of history, indeed to its very way of life. In recent years, these communities have played host to wrenching debates over wh

As we move into the next century, the pace of the health care business will increase. Only organizations that can anticipate and execute their strategies accordingly will survive. We can foresee some of these changes already: the growing power of consumers to manage their own care; the role of the Internet in changing communication channels; the financial success of lifestyle drugs in the marketplace; the use of smart agents to optimize the selection, purchase, and delivery of personalized heal

Amersham Pharmacia's GeneQuant pro Why buy the farm when all you need is milk? That seems to be the thinking behind the GeneQuant pro from Amersham, a spectrophotometer designed specifically for the molecular biology laboratory. No full-range spectrophotometer with UV-vis crossover, this instrument uses just the essential wavelengths needed for molecular biology: 230, 260, 280, 320, 595, and 600 nm. Instead of reporting why each wavelength is used, it is easier to describe the GeneQuant pro b

Are you resigned to doing cell cultures the old-fashioned way, complacently swabbing cells onto collagen or gel platforms? Or have you always believed there must be a better way? The answer to your problems may lie within the matrix--the Cellfoam™ matrix, that is. But what is the matrix, you ask? Cellfoam is a three-dimensional, highly porous structure for the manipulation of adherent and nonadherent cells. Cytomatrix, a small biotech company in Woburn, Mass., has grown difficult cells s

Do you routinely run DNA preps for PCR amplification? This is a common procedure in many laboratories. However, it is not always necessary to perform DNA preps prior to PCR. In many circumstances, all you need is lysis of the cells and release of the DNA. Microzone in the United Kingdom has recently introduced microLYSIS, a reagent designed to lyse a wide variety of different cell types prior to PCR. MicroLYSIS is a proprietary mixture of detergents formulated to lyse cells in less than 15 minut